Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study.

Heervä E, Carpelan A, Kurki S, Sundström J, Huhtinen H, Rantala A, Ålgars A, Ristamäki R, Carpén O, Minn H.

Acta Oncol. 2017 Dec 23:1-8. doi: 10.1080/0284186X.2017.1420230. [Epub ahead of print]

PMID:
29275667
2.

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics.

Birkman EM, Mansuri N, Kurki S, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O.

Virchows Arch. 2018 Mar;472(3):369-382. doi: 10.1007/s00428-017-2240-x. Epub 2017 Oct 19.

3.

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

Korkeila EA, Salminen T, Kallio R, Mikkola M, Auvinen P, Pyrhönen S, Ristamäki R.

Support Care Cancer. 2017 Sep;25(9):2771-2777. doi: 10.1007/s00520-017-3689-5. Epub 2017 Apr 20.

4.

A nationwide study on parathyroid carcinoma.

Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, Kekäläinen P, Tamminen M, Ristamäki R, Knutar O, Löyttyniemi E, Niskanen L, Väisänen M, Heiskanen I, Välimäki MJ, Laakso M, Haglund C, Arola J, Schalin-Jäntti C.

Acta Oncol. 2017 Jul;56(7):991-1003. doi: 10.1080/0284186X.2017.1306103. Epub 2017 Mar 31.

PMID:
28362521
5.

Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.

Heervä E, Lavonius M, Jaakkola P, Minn H, Ristamäki R.

J Gastrointest Cancer. 2017 Feb 23. doi: 10.1007/s12029-017-9927-8. [Epub ahead of print]

PMID:
28229371
6.

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.

Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.

7.

[Streamlined treatment pathway for a colorectal cancer patient].

Rantala A, Ristamäki R, Keränen U.

Duodecim. 2016;132(12):1165-9. Finnish.

PMID:
27483633
8.

[Principles of oncologic drug therapy following surgery for bowel cancer].

Ristamäki R, Ålgars A.

Duodecim. 2016;132(12):1155-9. Review. Finnish.

PMID:
27483631
9.

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.

Birkman EM, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O.

BMC Cancer. 2016 Jul 7;16:406. doi: 10.1186/s12885-016-2456-1.

10.

[Drug therapy of advanced pancreatic neuroendocrine tumor].

Ristamäki R, Tarkkanen M.

Duodecim. 2016;132(7):641-6. Review. Finnish.

PMID:
27188088
11.

Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O.

PLoS One. 2014 Jun 18;9(6):e99590. doi: 10.1371/journal.pone.0099590. eCollection 2014.

12.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P.

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

13.

ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.

Avoranta ST, Korkeila EA, Ristamäki RH, Syrjänen KJ, Carpén OM, Pyrhönen SO, Sundström JT.

Hum Pathol. 2013 Jun;44(6):966-74. doi: 10.1016/j.humpath.2012.10.003. Epub 2013 Jan 17.

PMID:
23332924
14.

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.

Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S, Sarhadi VK.

Cancer Genet. 2012 Nov;205(11):545-51. doi: 10.1016/j.cancergen.2012.08.003. Epub 2012 Oct 23.

PMID:
23098991
15.

Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients.

Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundström J, Salmi M, Ristamäki R, Jalkanen S.

Int J Cancer. 2012 Aug 15;131(4):864-73. doi: 10.1002/ijc.26457. Epub 2011 Nov 8.

16.

MicroRNA profiling differentiates colorectal cancer according to KRAS status.

Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S.

Genes Chromosomes Cancer. 2012 Jan;51(1):1-9. doi: 10.1002/gcc.20925. Epub 2011 Sep 15.

PMID:
21922590
17.

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.

Ålgars A, Lintunen M, Carpén O, Ristamäki R, Sundström J.

Br J Cancer. 2011 Jul 12;105(2):255-62. doi: 10.1038/bjc.2011.223. Epub 2011 Jun 21.

18.

[Changing prognosis and treatment of gastric cancer].

Ristamäki R, Salminen P, Kokkola A, Ristimäki A.

Duodecim. 2010;126(20):2363-71. Finnish.

PMID:
21125750
19.

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S.

Neoplasia. 2009 Jul;11(7):629-36.

20.

Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients.

Bendardaf R, Ristamaki R, Syrjanen K, Pyrhonen S.

World J Gastroenterol. 2008 Oct 28;14(40):6218-23.

21.

Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer.

Bendardaf R, Lamlum H, Ristamäki R, Syrjänen K, Pyrhönen S.

Oncol Rep. 2008 Nov;20(5):999-1004.

PMID:
18949393
22.

Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S.

Acta Oncol. 2008;47(6):1046-53.

PMID:
17943475
23.

MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases.

Bendardaf R, Buhmeida A, Ristamäki R, Syrjänen K, Pyrhönen S.

Scand J Gastroenterol. 2007 Dec;42(12):1473-8.

PMID:
17852862
24.

Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S.

Tumour Biol. 2007;28(4):212-20. Epub 2007 Aug 24.

PMID:
17717427
25.

Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.

Bendardaf R, Elzagheid A, Lamlum H, Algars A, Korkeila E, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S.

Scand J Gastroenterol. 2007 Apr;42(4):471-6.

PMID:
17454857
26.

Kolorektaalisyövän hoito on monen erikoisalan yhteistyötä.

Osterlund P, Ristamäki R, Pyrhönen S.

Duodecim. 2006;122(22):2669-71. Finnish. No abstract available.

PMID:
17240890
27.

DNA image cytometry is a useful adjunct tool in the prediction of disease outcome in patients with stage II and stage III colorectal cancer.

Buhmeida A, Algars A, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S.

Oncology. 2006;70(6):427-37. Epub 2007 Jan 12.

PMID:
17220640
28.

Comparison of CD44 expression in primary tumours and metastases of colorectal cancer.

Bendardaf R, Algars A, Elzagheid A, Korkeila E, Ristamäki R, Lamlum H, Collan Y, Syrjänen K, Pyrhönen S.

Oncol Rep. 2006 Oct;16(4):741-6.

PMID:
16969488
29.

E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome.

Elzagheid A, Algars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S.

World J Gastroenterol. 2006 Jul 21;12(27):4304-9.

30.

Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma.

Buhmeida A, Algars A, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S.

Anticancer Res. 2006 Jan-Feb;26(1B):455-62.

31.

Nuclear area is a prognostic determinant in advanced colorectal cancer.

Buhmeida A, Ristamäki R, Lamlum H, Bendardaf R, Heikkilä S, Collan Y, Syrjänen K, Pyrhönen S.

Anticancer Res. 2005 Jul-Aug;25(4):3083-8.

32.

Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.

Bendardaf R, Lamlum H, Elzagheid A, Ristamäki R, Pyrhönen S.

Oncol Rep. 2005 Sep;14(3):657-62.

PMID:
16077970
33.

E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer.

Bendardaf R, Elzagheid A, Lamlum H, Ristamäki R, Collan Y, Pyrhönen S.

Oncol Rep. 2005 May;13(5):831-5.

PMID:
15809746
34.

Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.

Bendardaf R, Lamlum H, Ristamäki R, Algars A, Collan Y, Pyrhönen S.

Oncology. 2004;66(1):46-52.

PMID:
15031598
35.

Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma.

Bendardaf R, Lamlum H, Vihinen P, Ristamäki R, Laine J, Pyrhönen S.

Oncology. 2003;65(4):337-46.

PMID:
14707454
36.

CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer.

Bendardaf R, Lamlum H, Ristamäki R, Pyrhönen S.

Oncol Rep. 2004 Jan;11(1):41-5.

PMID:
14654900
37.

Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma.

Bendardaf R, Ristamäki R, Kujari H, Laine J, Lamlum H, Collan Y, Pyrhönen S.

Oncology. 2003;64(4):435-42.

PMID:
12759543
38.

Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region.

Maula SM, Luukkaa M, Grénman R, Jackson D, Jalkanen S, Ristamäki R.

Cancer Res. 2003 Apr 15;63(8):1920-6.

39.

Novel serum inflammatory markers in acute appendicitis.

Paajanen H, Mansikka A, Laato M, Ristamäki R, Pulkki K, Kostiainen S.

Scand J Clin Lab Invest. 2002;62(8):579-84.

PMID:
12564616
40.

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.

Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, Linné T, Frödin JE, Boussard B, Oulid-Aïssa D, Pyrhönen S.

Ann Oncol. 2002 Dec;13(12):1868-73.

PMID:
12453854
41.

The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.

Maula S, Huuhtanen RL, Blomqvist CP, Wiklund TA, Laurila P, Ristamäki R.

Br J Cancer. 2001 Jan;84(2):244-52.

42.

Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.

Mäenpää H, Ristamäki R, Virtamo J, Franssila K, Albanes D, Joensuu H.

Leuk Lymphoma. 2000 May;37(5-6):585-92.

PMID:
11042519
43.

Serum CD44 in non-Hodgkin's lymphoma.

Ristamäki R, Joensuu H, Jalkanen S.

Leuk Lymphoma. 1999 May;33(5-6):433-40. Review.

PMID:
10342571
44.

Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.

Ristamäki R, Joensuu H, Hagberg H, Kalkner KM, Jalkanen S.

Int J Cancer. 1998 Jun 19;79(3):221-5.

45.

Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.

Ristamäki R, Joensuu H, Lappalainen K, Teerenhovi L, Jalkanen S.

Blood. 1997 Nov 15;90(10):4039-45.

46.

Origin and function of circulating CD44 in non-Hodgkin's lymphoma.

Ristämaki R, Joensuu H, Grön-Virta K, Salmi M, Jalkanen S.

J Immunol. 1997 Mar 15;158(6):3000-8.

PMID:
9058839
47.

[From bone marrow transplantation to blood stem cell transplantation. Experiences from the first 100 autologous stem cell transplantation in Turku].

Remes K, Rajamäki A, Grenman S, Itälä M, Kauppila M, Nikoskelainen J, Pelliniemi TT, Ristamäki R, Salmi TT, Salmi T, Salminen E, Vanharanta R, Toivanen A.

Duodecim. 1997;113(3):219-28. Finnish. No abstract available.

PMID:
11370030
48.

Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy.

Villikka K, Muhonen T, Ristamäki R, Teerenhovi L, Joensuu H.

Acta Oncol. 1997;36(6):619-24.

PMID:
9408153
49.

Does soluble CD44 reflect the clinical behavior of human cancer?

Ristamäki R, Joensuu H, Jalkanen S.

Curr Top Microbiol Immunol. 1996;213 ( Pt 3):155-66. Review. No abstract available.

PMID:
8815003
50.

CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.

Ristamäki R, Joensuu H, Söderström KO, Jalkanen S.

J Pathol. 1995 Jul;176(3):259-67.

PMID:
7545748

Supplemental Content

Loading ...
Support Center